The first batch of Chinese Simeglutide generic drugs are already on the way, weight loss drugs will enter the "cabbage price" era.

With the expiration of the core molecular patent for the GLP-1 drug semaglutide in China in March, a large number of domestically produced semaglutide generic drugs are being approved. After the opening of the Hong Kong stock market on February 27, the stock price of Ninepolar Genetics rose by more than 4% at one point. The company recently announced that the application for the semaglutide biosimilar drug Jigenqin has been officially accepted by the Chinese National Medical Products Administration, with the indication for weight management in obese or overweight populations. According to public information, more than ten domestic pharmaceutical companies including Ninepolar Genetics, Lijun Group, Huadong Medicine, Qilu Pharmaceutical, and Zhen Dai Tianqing are expected to launch their semaglutide generic drugs in the near future, with over ten in Phase III clinical trials, and a price war is imminent. Regarding the efficacy of generic drugs that the market is concerned about, Ninepolar Genetics stated that based on a Phase III clinical study involving over 370 obese patients, Jigenqin is "comparable in clinical safety and changes in patient weight after 44 weeks of treatment" to the reference drug. The so-called reference drug is the semaglutide weight loss drug from Novo Nordisk. An endocrinology expert told reporters that with more generic drugs entering the market, weight loss drugs will soon enter a "bargain price" era. Previously, Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, drugs used for diabetes indications, saw significant price reductions after being included in medical insurance.